Linezolid Versus Ceftriaxone/Cefpodoxime in Patients Hospitalized for the Treatment of Streptococcus pneumoniae Pneumonia

References

• Bernstein JM. Treatment of community-acquired pneumonia – IDSA guidelines. Chest 1999; 115: 9S–13S.
   Google Scholar
• Brown RB. Community-acquired pneumonia: diagnosis and therapy of older adults. Geriatrics 1993; 48: 43–50.
   PubMed Web of Science ®Google Scholar
• Campbell GD. Overview of community-acquired pneumonia: prognosis and clinical features. Med Clin North Am 1994; 78: 1035–48.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Stone RA, Singer DE, Coley CM, Marrie TJ, Lave JR, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team (PORT) cohort study. Arch Intern Med 1999; 159: 970–80.
   PubMed Web of Science ®Google Scholar
• Ortiz CR, La Force FM. Prevention of community-acquired pneumonia. Med Clin North Am 1994; 78: 1173–83.
   PubMed Web of Science ®Google Scholar
• Ewig S. Community-acquired pneumonia: definition, epidemiology, and outcome. Semin Respir Infect 1999; 14: 94–102.
   PubMedGoogle Scholar
• Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimor EA, eds. Vaccines, 2nd edn. Philadelphia, PA: W.B. Saunders, 1994.
   Google Scholar
• Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995: 2128–46.
   Google Scholar
• Bartlett JG. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect 1997; 12: 329–33.
   PubMedGoogle Scholar
• Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835–42.
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999; 25: 198–206.
   PubMed Web of Science ®Google Scholar
• Marrie TJ. New aspects of old pathogens of pneumonia. Med Clin North Am 1994; 78: 987–95.
   PubMed Web of Science ®Google Scholar
• Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med 1999; 107 (Suppl 1A): 77S–85S.
   Google Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9.
   Google Scholar
• Crook DWM, Spratt BG. Multiple antibiotic resistance in Streptococcus pneumoniae. Br Med Bull 1998; 54: 595–610.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628–44.
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? Drugs 1999; 57: 851–3.
   Google Scholar
• Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996; 39: 673–9.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, Allison J, Kilburn O, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45.
   PubMed Web of Science ®Google Scholar
• Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H, et al. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 1999; 5: 939–46.
   PubMed Web of Science ®Google Scholar
• Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1988; 32: 1341–6.
   Google Scholar
• Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456–62.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci Antimicrob Agents Chemother 1996; 40: 1745–7.
   PubMed Web of Science ®Google Scholar
• Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ Jr, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996; 40: 1508–13.
   Google Scholar
• Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997; 41: 465–7.
   Google Scholar
• Mercier RC, Penzak SR, Rybak MJ. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 2573–5.
   Google Scholar
• Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132–6.
   PubMed Web of Science ®Google Scholar
• Jones RN, Pfaller MA, Erwin ME, Beach ML. Antimicrobial activity of linezolid (U-100766) tested against 7,599 recent clinical isolates from over 50 medical center laboratories. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26–29 September, 1999. Washington D.C.: American Society for Microbiology, 1999: 264.
   Google Scholar
• Schülin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520–3.
   PubMed Web of Science ®Google Scholar
• Cammarata SK, Standiford H, Todd WM, Oliphant TH, Hafkin B. Linezolid eradicates common pathogens in community-acquired pneumonia: summary of three studies. In: Program and Abstracts of the 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, 28–31 May, 2000. Taufkirchen, Germany: European Society of Microbiology and Infectious Diseases, 2000.
   Google Scholar
• Cammarata SK, Schueman LK, Timm JA, Hempsall KA, Chang W, Oliphant TH, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase iii trial. In: Program and Abstracts of the American Thoracic Society 2000, Toronto, Ont., 5–10 May, 2000. New York: American Thoracic Society, 2000: 654 (E73).
   Google Scholar
• Molinari M, Garrera G, Pimm MHJ, DeCian W, Aronkyto T, Giamarellou H. Linezolid in the treatment of outpatients with community-acquired pneumonia: European results. In: Program and Abstracts of the 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, 28–31 May, 2000. Taufkirchen, Germany: European Society of Microbiology and Infectious Diseases, 2000.
   Google Scholar
• Watts JL, Salmon SA, Yancey RJ Jr, Ford CW. In vitro activity of two oxazolidinone antimicrobial agents (U-100592 and U-100766) against Mycoplasma spp. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 17–20 September, 1995. Washington, D.C.: American Society for Microbiology, 1995.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement. NCCLS document M100- S12. Volume 22, No. 1. Wayne, PA: NCCLS, 2001.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society for Clinical Microbiology and Infectious Diseases (ECSMID). Linezolid breakpoints. EUCAST Definitive Document, E. Def 4.1 CMI 2000; 7:283–4.
   Google Scholar
• Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991; 27 (Suppl A): S117–24.
   Google Scholar
• Genne D, Siegrist HH, Humair L, Janin-Jaquat B, de Torrente A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16: 783–8.
   Google Scholar
• Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6.
   Google Scholar
• Vergis EN, Yu VL. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Semin Respir Infect 1997; 12: 322–8.
   PubMedGoogle Scholar
• Baglioni S, Dottorini M, Sini GM, Eslami A, Vecchiarelli A, Todisco T. Prediction of pulmonary immunodeficiency in chronic bronchitis by cutaneous hypoergy to multitest. Dev Biol Stand 1992; 77: 167–73.
   PubMedGoogle Scholar
• Todisco T, Vecchiarelli A, Dottorini M, Eslami A, Bertotto A, Massucci M, et al. Interferon-gamma (r-IFN-γ) induced activation of alveolar macrophages (AM) from anergic patients with chronic obstructive pulmonary disease (COPD). J Biol Regul Homeost Agents 1992; 6: 87–92.
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Dottorini M, Puliti M, Todisco T, Cenci E, Bistoni F. Defective candidacidal activity of alveolar macrophages and peripheral blood monocytes from patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1049–54.
   PubMed Web of Science ®Google Scholar
• Aszkenasy DM, George RC, Begg NT. Pneumococcal bacter- aemia and meningitis in England and Wales 1982 to 1992. CDR Rev 1995; 5: R45–50.
   Google Scholar
• Steven N, Wright P. Pneumococcal immunisation and the healthy elderly [Letter]. Lancet 1992; 340: 1036–7.
   PubMed Web of Science ®Google Scholar